TY - JOUR
T1 - Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials
T2 - a Harmonising Outcome Measures for Eczema (HOME) statement
AU - the HOME initiative collaborators
AU - Spuls, P. I.
AU - Gerbens, L. A.A.
AU - Simpson, E.
AU - Apfelbacher, C. J.
AU - Chalmers, J. R.
AU - Thomas, K. S.
AU - Prinsen, C. A.C.
AU - von Kobyletzki, L. B.
AU - Singh, J. A.
AU - Williams, H. C.
AU - Schmitt, J.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has defined four core outcome domains for a core outcome set (COS) to be measured in all atopic eczema (AE) trials to ensure cross-trial comparison: clinical signs, symptoms, quality of life and long-term control. Objectives: The aim of this paper is to report on the consensus process that was used to select the core instrument to consistently assess symptoms in all future AE trials. Methods: Following the HOME roadmap, two systematic reviews were performed which identified three instruments that had sufficient evidence of validity, reliability and feasibility to be considered for the final COS. Results: At the fourth international HOME meeting, there was broad consensus among all stakeholders that the Patient-Oriented Eczema Measure (POEM) should be used as the core instrument (87·5% agreed, 9·4% unsure, 3·1% disagreed). Conclusions: All relevant stakeholders are encouraged to use POEM as the chosen instrument to measure the core domain of symptoms in all future AE clinical trials. Other instruments of interest can be used in addition to POEM.
AB - Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has defined four core outcome domains for a core outcome set (COS) to be measured in all atopic eczema (AE) trials to ensure cross-trial comparison: clinical signs, symptoms, quality of life and long-term control. Objectives: The aim of this paper is to report on the consensus process that was used to select the core instrument to consistently assess symptoms in all future AE trials. Methods: Following the HOME roadmap, two systematic reviews were performed which identified three instruments that had sufficient evidence of validity, reliability and feasibility to be considered for the final COS. Results: At the fourth international HOME meeting, there was broad consensus among all stakeholders that the Patient-Oriented Eczema Measure (POEM) should be used as the core instrument (87·5% agreed, 9·4% unsure, 3·1% disagreed). Conclusions: All relevant stakeholders are encouraged to use POEM as the chosen instrument to measure the core domain of symptoms in all future AE clinical trials. Other instruments of interest can be used in addition to POEM.
UR - http://www.scopus.com/inward/record.url?scp=85014113737&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/bjd.15179
DO - https://doi.org/10.1111/bjd.15179
M3 - Article
C2 - 27858989
SN - 0007-0963
VL - 176
SP - 979
EP - 984
JO - British Journal of Dermatology
JF - British Journal of Dermatology
IS - 4
ER -